Oxford University researchers have published results from the first clinical study investigating extracorporeally triggered drug delivery using focused ultrasound in the Lancet Oncology.
Safety and Feasibility of Ultrasound-triggered Targeted Drug Delivery of Doxorubicin from Thermosensitive Liposomes in Liver Tumours (TARDOX): A Single-centre, Open-label, Phase 1 Trial presents results from 10 patients with chemotherapy-resistant liver tumors who were treated with a new delivery method that uses focused ultrasound to gently heat target tumors in order to release highly targeted chemotherapy from temperature-sensitive nanocarriers, or liposomes. The study demonstrated that, on average, this technique enables an almost four-fold increase in the drug concentration inside the tumor, mediating responses in some tumor types that do not typically respond to doxorubicin. This work has earned coverage in the oncology, precision medicine, and focused ultrasound communities.
Selected Media Coverage
Zenopa | Ultrasound to Deliver Medicine to ‘Inoperable’ Liver Cancer Tumours 7/20/18
MedWireNews | Ultrasound-induced Targeted Doxorubicin Delivery Feasible for Liver Tumors 7/16/18
The Engineer | Focused Ultrasound Points to Precision Cancer Medicine 7/11/18
United Press International (UPI) | Study: Ultrasound Better Targets Cancer Drugs 7/10/18
The Times | Treatment Turns Up Heat on Tumours 7/10/18
Medscape | Focused Ultrasound Increases Drug Delivery to Liver Tumors 7/9/18